Erbitux (Cetuximab) - Investigational Biological Cancer Therapy, No Country
Key Data:
Drug (brand/generic)
Erbitux (cetuximab, C225)
Company/licensee
ImClone Systems Inc/ Bristol-Myers Squibb/ Merck KGaA
Therapy class
Anti-neoplastic agent
Product description
Anti-EGFR MAb
Current indication
Metastatic colorectal cancer, locally advanced squamous cell carcinoma of the head and neck
Market sector
Oncology
Development status
Approved
